GlassScriptPhysician profile
Paulo Calderon
NPI 1467637819
$4,151.42
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,405 · 2020: $805 · 2021: $582 · 2022: $1,029 · 2023: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $789.58 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $457.61 | 2019-2023 | Wegovy, Saxenda, Rybelsus |
| Glaxosmithkline, LLC. | $395.09 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $266.54 | 2020-2023 | Qulipta |
| Amarin Pharma, INC. | $264.10 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.07 | 2020-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $208.76 | 2019-2022 | |
| Pfizer INC. | $204.79 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $145.06 | 2019-2023 | Xarelto |
| Allergan, INC. | $123.20 | 2019-2020 | |
| Lilly USA, LLC | $117.57 | 2020-2023 | Emgality, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $108.17 | 2019-2021 | |
| Astellas Pharma US INC | $98.91 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $84.65 | 2019 | |
| Medtronic, INC. | $74.47 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paulo Calderon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.